0      0

21EL-674 On-Demand eCast: Simple Transfusion vs. Exchange Transfusion and Future Therapies in Patients with Sickle Cell Disease

Expiration Date: Sep 14, 2024

Credits: None available.

Live Program Date: Wednesday, September 15, 2021
Program Number: 21EL-674

Educational Track: Technical/Clinical
Topics: Apheresis, Cellular Therapy, Collection, Complications, Inventory, Management Operations, Outcomes, Outcomes/Engagement, Patient Blood Management, Patient Transfusion, Special Patients and Situations, Therapeutic Apheresis, Therapeutic Goals, Transfusion Process, Transfusion Safety
Intended Audience: Directors, Hospital Blood Banks, Hospitals, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
Teaching Level: Advanced, Intermediate

(titles and affiliations at the time of the live program)
Director/Moderator: Huy P. Pham, MD, MPH, Medical Director, National Marrow Donor Program (NMDP), Seattle, WA
Speakers: Patricia A. Shi, MD, Medical Director, New York Blood Center, New York, NY
Ross Fasano, MD, Associate Professor, Emory University, Atlanta, GA
Monika Paroder, MD, PhD, Assistant Professor, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

Program Description
Sickle cell disease is affected approximately 100,000 people in the United States. It is a major public health concern and the patients have a significant morbidity and mortality. At this time, transfusion of red blood cells (RBCs) is one of the main treatment strategies for this disease. However, transfusion is potentially associated with multiple complications, including transfusion-transmitted infections and alloimmunizations.

Given that there are few quality studies investigated the effect of simple vs. exchange transfusion in patients with sickle cell disease, this program will summarize the current data and expert opinion on the use of each treatment modality. Key considerations that physicians should be aware of when choosing between treatment options as well as challenges in pediatric patients will also be addressed. Lastly, novel therapies in the treatment of sickle cell disease, including cellular therapies, will be discussed.

Learning Objectives
After participating in this educational activity, participants should be able to:

  • Discuss considerations for simple vs. exchange transfusions in patients with sickle cell disease.
  • Summarize key considerations in using different treatment options in pediatric patients.
  • Describe current novel therapies, including cellular therapies, as treatment modalities in sickle cell disease.

How to Claim Continuing Education Credit

  • Single Viewers: if you registered as a single viewer, complete the evaluation found on the "CE Information" tab after watching the video. By submitting the evaluation, you are attesting to watching the presentation in its entirety.
  • Group Viewers: This is applicable for groups/facilities that purchased Group Viewing access for this program (registration will be verified prior to processing a group viewing attendance log). Group Viewing Coordinators should submit the attendance log to eLearning@aabb.org within 72 hours of the completion/viewing date. Once AABB receives an attendance log, each participant on the attendance log will be granted access as a single viewer to this program and will be required to complete the evaluation in order to claim continuing education credit. Each participant will be required to have an AABB account in order to access this program/platform. If a participant does not have an account, he/she can create one using the same email address provided on the attendance log.



By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

All relevant financial relationships have been mitigated.


  • 1.50 - General Continuing Education (GEN)
  • 1.50 - Florida Lab Personnel (FLP)
  • 1.50 - California Lab Personnel (CLP)